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Lethal mutagenesis is the mechanism of action of ribavirin against poliovirus (PV) and 3 
numerous other RNA viruses.  However, there is still considerable debate regarding the 4 
mechanism of action of ribavirin against a variety of RNA viruses.  Here we show by 5 
using T7 RNA polymerase mediated production of PV genomic RNA, PV polymerase-6 
catalyzed primer extension and cell-free PV synthesis that a pyrimidine ribonucleoside 7 
triphosphate analogue (rPTP) with ambiguous basepairing capacity is an efficient 8 
mutagen of the PV genome.  The in vitro incorporation properties of rPTP are superior to 9 
ribavirin triphosphate.  We observed a log-linear relationship between virus titer 10 
reduction and the number of rPMP molecules incorporated.  A PV genome encoding a 11 
high-fidelity polymerase was more sensitive to rPMP incorporation, consistent with 12 
diminished mutational robustness of high-fidelity PV.  The nucleoside (rP) did not 13 
exhibit antiviral activity in cell culture owing to the inability of rP to be converted to 14 
rPMP by cellular nucleotide kinases.  rP was also a poor substrate for herpes simplex 15 
virus thymidine kinase.  The block to nucleoside phosphorylation could be bypassed by 16 
treatment with the P nucleobase, which exhibited both antiviral activity and mutagenesis, 17 
presumably a reflection of rP nucleotide formation by a nucleotide salvage pathway.  18 
These studies provide additional support for lethal mutagenesis as an antiviral strategy, 19 
suggest that rPMP prodrugs may be highly efficacious antiviral agents, and provide a new 20 
tool to determine the sensitivity of RNA virus genomes to mutagenesis as well as 21 



















Viruses with RNA genomes are the causative agents of numerous infectious 3 
diseases of clinical relevance, and some are considered significant threats as agents of 4 
bioterrorism.  With the exception of drugs targeting HIV, few therapeutics exist for the 5 
treatment of RNA virus infection.  Thus, the development of broad-spectrum antiviral 6 
treatments for RNA virus infections remains a crucial medical research goal. 7 
 In the past several years, a number of studies have appeared supporting the use of 8 
lethal mutagenesis as a general antiviral strategy (reviewed in (14)).  RNA viruses 9 
replicate with a high error frequency due to the lack of proofreading activity in the virus-10 
encoded polymerases(11, 50).  The resulting heterogeneous virus population has often 11 
been termed a quasispecies(12).  Quasispecies theory predicts the existence of an error 12 
threshold, an upper limit to the mutation frequency beyond which genome viability is 13 
severely compromised.  In one study, poliovirus (PV) viability was reduced 99.3% when 14 
the mutation frequency was increased only 9.7-fold beyond the normal level(6).  Thus, 15 
lethal mutagenesis is an antiviral strategy which aims to increase the mutation rate of 16 
RNA viruses beyond the threshold where virus viability can be maintained. 17 
 The antiviral nucleoside analogue ribavirin has been demonstrated to act via lethal 18 
mutagenesis in vitro against a variety of RNA viruses, including poliovirus(7), hepatitis C 19 
virus(28, 60), GB virus B(27), Hantaan virus(48), food-and-mouth disease virus(1),  and 20 
West Nile virus(9).  Furthermore, other antiviral nucleoside and nucleobase analogues 21 
have been proposed to act via lethal mutagenesis, most notably 5-hydroxy-2′-22 
















and-mouth disease virus(49),  and 5-fluorouracil against poliovirus and vesicular 1 
stomatitis virus(24), lymphocytic choriomeningitis virus(16, 46), and foot-and-mouth 2 
disease virus(41, 42, 49). 3 
 However, there is still debate regarding the capacity for ribavirin to act as a lethal 4 
mutagen, particularly whether direct incorporation of a mutagen into viral RNA is 5 
sufficient for antiviral activity.  Ribavirin has been shown to act via a number of different 6 
mechanisms, all of which may contribute to its antiviral activity (reviewed in (15)).  7 
In addition, the applicability of quasispecies theory, error catastrophe, and lethal 8 
mutagenesis concepts to viral evolution has been controversial(10, 25, 26, 38).  An 9 
important theoretical advance was made by Schuster and Swetina in proposing “survival 10 
of the flattest”(47).  Using digital organisms, Wilke et al. demonstrated that for 11 
populations evolving at high mutation rates, high fitness organisms could be outcompeted 12 
by lower-fitness organisms, if the latter exist in a “flatter” region of the fitness 13 
landscape(59).  That is, populations subjected to high mutation rates will evolve to exist 14 
in “flat” regions of the fitness landscape where the density of neutral mutations is high.  15 
This has become known as “mutational robustness”(54). 16 
Whereas lethal mutagenesis and “survival of the flattest” have been described 17 
theoretically and in digital models(58, 59), there has been little advance in these theories 18 
from an in vitro or in vivo perspective.  The interplay between mutational load, 19 
polymerase fidelity, and mutational robustness is largely unexplored.  One approach to 20 
evaluating these theories in live virus populations is by manipulating population error 21 
















We have previously investigated the use of “universal” bases with minimal 1 
hydrogen bonding potential as lethal mutagens of PV(17, 19).  Here we investigate the 2 
antiviral and mutagenic potential of a nucleoside analogue with the capacity to stably 3 
base pair with two natural nucleobases.  The ribonucleoside analogue 6-(β-D-4 
ribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one (hereafter referred to as 5 
rP; Figure 1) is a pyrimidine analogue with degenerate hydrogen-bonding properties(51). 6 
Tautomerization of the nucleobase (named P) allows for two distinct configurations of 7 
hydrogen bond donors and acceptors, permitting stable base pairing with either adenine 8 
or guanine (Figure 1). 9 
Previous work with the ribonucleoside analogue (rP) and related 2′-10 
deoxyribonucleoside analogue (dP) has established that they can be utilized as substrates 11 
by multiple RNA and DNA polymerases (22, 35, 52), and incorporation of rP into a 12 
biologically active RNA molecule had little effect on its structure or activity(35).  13 
Furthermore, dP was shown to induce the predicted transition mutations in E. coli after 14 
phosphorylation through the bacterial thymidine kinase pathway(40).  dP has also been 15 
shown to induce C-to-U and U-to-C transition mutations at a high rate in an in vitro 16 
retroviral replication model(36).  Templates containing rPMP were also able to direct 17 
incorporation of either G or A by HIV and AMV reverse transcriptases(52).  18 
Accordingly, rP is considered to be an ambiguous pyrimidine nucleoside analogue with 19 
high potential to induce mutagenesis if utilized as a substrate by RNA virus polymerases 20 
during genome replication.  Herein, we evaluated the ability of rP and rPTP to function as 21 
















We find that incorporation of rP into PV genomes synthesized in vitro resulted in 1 
substantial loss of RNA specific infectivity, indicating that incorporation of a mutagenic 2 
nucleotide into viral RNA is sufficient to reduce virus fitness.  Furthermore, rPTP is a 3 
highly efficient and promiscuous substrate for the PV-encoded RNA-dependent RNA 4 
polymerase, 3Dpol.  Unfortunately, rP does not have antiviral activity in cell culture due to 5 
insufficient accumulation of the active triphosphate, although treatment with the 6 
nucleobase (P) demonstrated mild antiviral activity and mutagenesis.  In addition, a 7 
poliovirus variant with a high-fidelity polymerase (G64S) demonstrated increased 8 
sensitivity to direct incorporation of this nucleotide into transcribed genomes.  Direct 9 
incorporation of rP into viral RNA genomes can therefore be used to elucidate the effect 10 
of mutation frequency on the infectivity of viral genomes and dynamics of the resulting 11 
virus population independent of the error rate of the cognate polymerase or the ability of 12 

















MATERIALS AND METHODS 1 
 2 
Cells and viruses.  HeLa S3 cells (obtained from ATCC) were maintained in D-MEM/F-3 
12 media supplemented with 2% dialyzed fetal bovine serum, 50 U/ml penicillin and 50 4 
µg/ml streptomycin (Invitrogen).  Cells were maintained at 37 °C in a 5% CO2 5 
atmosphere.  Antiviral activity assays were performed as previously described(19).  6 
Guanidine resistance assay was performed as previously described(7).  Statistical analysis 7 
was performed using Prism 4 for Windows (GraphPad Software, Inc.).  PV-WT and PV-8 
G64S virus stocks were generated by transfecting HeLa cells with full-length genome 9 
RNA transcribed using T7 RNA polymerase from a plasmid containing the viral cDNA 10 
(pMoRA or pMoRA-G64S) as previously described(21, 56).  Recovered virus was 11 
passaged a minimum of 5 times in HeLa cells to allow for diversification of the virus 12 
population from the initial cDNA sequence. 13 
 14 
Expression and purification of T7 RNA polymerase (RNAP). T7 RNAP was purified as 15 
previous described for PV 3Dpol (13) with the following modifications: (I) ammonium 16 
sulfate was added to 40 % saturation; (II) the phosphocellulose column was eluted using 17 
a linear gradient (6 column volumes) from 50 mM - 700 mM NaCl in Buffer A; (III) the 18 
Q-Sepharose column was loaded and washed, and the protein eluted using a linear 19 
gradient (6 column volumes) from 50 mM - 400 mM NaCl in Buffer A. Protein-20 
containing fractions were pooled as before. Additional steps to concentrate the protein 21 

















Incorporation of RTP by T7 RNA polymerase. Incorporation by T7 RNAP opposite 1 
templating bases cytosine or thymine in assembled enzyme-primer/template complexes 2 
was examined for RTP and the correct natural nucleotide (GTP opposite cytosine; ATP 3 
opposite thymine). Assay conditions were modified from (53).  The RNA primer 4 
sequence was 5′-UUUUGCCGCGCC-3′. The DNA template sequence providing 5 
templating C (bold, underlined) was 5′-GGGAATGTACGGCGCGGC-3′. The DNA 6 
template sequence providing templating T (bold, underlined) was 5′-7 
GGGAATGCATGGCGCGGC-3′. RNA primer was 5′-end labeled with γ32P-ATP by T4 8 
polynucleotide kinase according to the manufacturer’s protocol (New England BioLabs). 9 
Annealing of 32P-end-labeled RNA primer with DNA template was accomplished by 10 
heating to 90 °C for 1 min followed by cooling to 10 °C at a rate of 5 °C per min. T7 11 
RNAP was allowed to preassemble with primer/template duplex for 10 min at room 12 
temperature immediately prior to reactions. Reactions were at 30 °C for 30 or 180 s in 50 13 
mM HEPES pH 7.5, 10 mM 2-mercaptoethanol and 5 mM MgCl2 with 2 µM T7 RNAP, 14 
1 µM primer/template duplex, and 0.5 mM RTP or natural nucleotide. Reactions were 15 
initiated by addition of nucleotide and terminated by quenching in 100 mM EDTA/90% 16 
formamide gel loading dye. Reaction products were separated by denaturing PAGE and 17 
gels were visualized using a Typhoon 8600 Variable Mode Imager (Molecular 18 
Dynamics) as previously described (13). 19 
 20 
In vitro transcription by T7 RNA polymerase.  A plasmid containing the PV genomic 21 
cDNA under the control of a T7 promoter (pMoRA)(21) was linearized via digestion 22 
















contained 350 mM HEPES (pH 7.5), 32 mM magnesium acetate, 40 mM DTT, 2 mM 1 
spermidine, 7 mM each NTP (ATP, CTP, GTP, UTP), 0.5 µg linearized plasmid DNA, 2 
and 0.5 µg purified T7 RNA polymerase in a final volume of 0.02 ml.  rPTP was added at 3 
varying concentrations with an equimolar amount of magnesium acetate.  The mixture 4 
was incubated for 3 hours at 37 °C followed by 2 minutes centrifugation at 14,000 x g.  5 
The pellet was discarded and two units of RQ1 DNase (Promega) were added to the 6 
supernatant, followed by incubation at 37 °C for an additional 30 minutes to digest 7 
template DNA.  RNA was precipitated by addition of 0.05 ml 7.5 M lithium chloride with 8 
50 mM EDTA.  This mixture was frozen on dry ice for 15 minutes and centrifuged at 9 
14,000 x g for 30 minutes at 4 °C.  The supernatant was discarded and the RNA pellet 10 
was washed twice with 70% ethanol, air-dried, and resuspended in deionized water.  11 
Quality of full-length genomic RNA was verified by agarose gel, and RNA was 12 
quantitated by fluorescence in the presence of ethidium bromide by comparing to a 13 
known RNA standard. 14 
 15 
Digestion of T7-transcribed RNA to component nucleosides.  RNA digestion was 16 
performed essentially as previously published(5). Briefly, RNA suspended in ~20 µl 17 
deionized water (approximately 2 µg/µl) was denatured at 100 °C for 3 minutes then 18 
rapidly chilled in an ice-water slush.  One-tenth volume 0.1 M ammonium acetate (pH 19 
5.3) was added, followed by addition of 2 U nuclease P1 (MP Biochemicals) and 20 
incubation for 2 hours at 45 °C.  One-tenth volume of 1 M ammonium bicarbonate (pH 21 
















Corporation) and further incubation for 1 hour at 37 °C.  The solution was heated to 95 1 
°C for 10 minutes to inactivate enzymes prior to HPLC separation. 2 
 3 
HPLC separation and detection method.  HPLC separations were performed on a Hewlett 4 
Packard (Agilent) 1100 series instrument equipped with an in-line solvent degasser and 5 
diode array detector.  RNA digests were separated on an Aquasil C-18 column (4.6 x 250 6 
mm, 5 µm; Keystone Scientific Inc., [Thermo Electron Corp]) eluting with the following 7 
linear gradient (1 ml/min flow rate): 1 – 95 % acetonitrile (MeCN) in 100 mM monobasic 8 
potassium phosphate buffer (KH2PO4, pH = 6.0) over 15 minutes.  The phosphate buffer 9 
was prepared by dissolving KH2PO4 in distilled and deionized water (ddH2O) at 100 mM 10 
and adjusting the pH to 6.0 by addition of 10 % KOH (aqueous).  Acetonitrile employed 11 
in the separation was HPLC grade.  The elution of ribonucleosides (cytidine, uridine, 12 
adenosine, and guanosine) was detected at 254 nm; elution of rP was detected at 295 nm.  13 
Injection volumes for treatments ranged from 7.5 µl to 15 µl; the injector port was fitted 14 
with a 20 µl injection loop.  Peak areas were obtained by standard integration of the 15 
appropriate peak by the ChemStation for LC 3D software (Rev.A.09.03, Agilent 16 
Technologies). 17 
 18 
Generation of standard stocks and fitting of data points.  rP was dissolved in distilled and 19 
deionized water (ddH2O) at 2.5 mM concentration and serial dilutions were prepared.  20 
Ribonucleoside standards were prepared by serial dilution of 25 mM stocks of cytidine 21 
and uridine (in ddH2O) and guanosine and adenosine (in DMSO).  Individual analyses of 22 
















resulting peak areas (mAU) were plotted against the quantity of material injected 1 
(nmoles).  Linear regression analysis of the tabulated calibration lines found R2 > 0.99 for 2 
each of the standards. 3 
 4 
Identification of peaks and tabulation of the abundance of P in transcribed RNA.  The 5 
identity of nucleosides from the RNA digestion was assigned by doping the transcription 6 
mixture with known standards and observing an increase in the area of the corresponding 7 
peak (compared with non-doped analyses).  The relative abundance of each nucleoside in 8 
the transcriptional mix was determined by fitting the area of the separated peak to the 9 
corresponding standard line formula.  The percentage of rP in each RNA digestion was 10 
tabulated by dividing the nanomoles of rP by the total nanomoles of nucleosides in the 11 
sample. Each digestion was analyzed in triplicate, with the mean representing the average 12 
of these individual analyses.  As a control to ensure that residual rPTP was adequately 13 
washed away from transcribed RNA, a control experiment was performed in which 14 
transcription was performed with only the four natural nucleotides.  After digestion of the 15 
DNA template and immediately prior to lithium chloride precipitation, rPTP was added at 16 
the highest concentration used for transcription.  This RNA was precipitated, washed and 17 
digested, and the nucleosides were separated by HPLC as described above.  No rP was 18 
detected in this control experiment, indicating that unincorporated nucleotides were 19 


















Transfection and infectious center assays.  Infectious center assay to determine the 1 
specific infectivity of transcribed PV genomic RNA was performed as previously 2 
described(6).  HeLa S3 cells were detached via treatment with trypsin-EDTA 3 
(Invitrogen), washed with 1X PBS, and resuspended in 1X PBS at 3 x 106 cells/ml.  Cell 4 
suspension (0.4 ml) was mixed with 0-10 µg T7-transcribed RNA and transferred to an 5 
electroporation cuvette (0.2 mm gap; VWR international).  Electroporation was 6 
performed using a Gene Pulser (Bio-Rad) set at 500 microfarads and 130 volts.  7 
Electroporated cells were serially diluted in 10-fold increments in PBS, and 0.1 ml of 8 
each dilution and the undiluted electroporated cell suspension was plated onto 9 
subconfluent HeLa S3 monolayers plated the previous day at 5 x 105 cells/well in 6-well 10 
plates containing 1.5 ml growth media.  Cells were incubated for 1 hour at 37 °C to allow 11 
for attachment.  Wells were aspirated and the monolayers were covered with 3 ml of D-12 
MEM/F-12 with 2% dialyzed fetal bovine serum and 1X penicillin-streptomycin 13 
supplemented with 1% low melting point agarose (American Bioanalytical).  Plates were 14 
incubated for 3 days at 37 °C before removal of the agar plug and staining with 0.1% 15 
crystal violet solution in 20% ethanol for visualization of plaques.  For the experiments 16 
shown in Figure 4B, data was normalized such that for each individual experiment the 17 
number of plaques resulting from RNA transcribed in the absence of rPTP was set to 100. 18 
 For the experiment comparing wild type and G64S PV, RNA was transfected as 19 
described above.  Following electroporation, 0.2 ml cell suspension was added to 0.8 ml 20 
growth media and incubated in a 37 °C waterbath for 6 hours.  The cell suspension was 21 
















14,000 x g to remove cellular debris.  The supernatant was titered on HeLa cell 1 
monolayers for 3 days followed by staining with crystal violet solution. 2 
 3 
 4 
Nucleotide incorporation by PV 3Dpol in vitro.  PV 3Dpol was expressed and purified as 5 
previously described(13).  Extension assays utilizing symmetrical primer-template 6 
substrates (s/s) were performed as described(2).  s/s RNAs were synthesized by 7 
Dharmacon, Inc. and 5′-end labeled with γ32P-ATP by T4 polynucleotide kinase 8 
according to the manufacturer’s protocol (New England BioLabs).  Annealing of 32P-end-9 
labeled RNA primer to form the duplex substrate was accomplished by heating to 90 °C 10 
for 1 min followed by cooling to 10 °C at a rate of 5 °C per min.  3Dpol was incubated 11 
with the appropriate s/s duplex for 90 s at 30 °C to allow formation of preinitiation 12 
enzyme-RNA complexes.  Extension reactions were initiated by the addition of 13 
nucleotide and incubated at 30 °C for the indicated times.  The initiated reaction 14 
contained 1 µM 3Dpol, 1 µM s/s (0.5 µM duplex), 50 mM HEPES (pH 7.5), 10 mM 2-15 
mercaptoethanol, 5 mM MgCl2, 60 µM ZnCl2, and nucleoside triphosphate (NTP) as 16 
indicated for each experiment.  Reactions were quenched by addition of EDTA (pH 8.0) 17 
to 50 mM.  Polymerase was diluted immediately prior to use in 50 mM HEPES (pH 7.5), 18 
10 mM 2-mercaptoethanol, 60 µM ZnCl2 and 20% glycerol.  For all experiments, 100 µM 19 
non-radiolabeled s/s “trap” was added along with initiating nucleotide to prevent 20 
reinitiation of dissociated enzyme.  Product was added to an equal volume of loading 21 
buffer (90% formamide, 0.025% bromphenol blue, and 0.025% xylene cyanol) and 22 
















acrylamide, 1X TBE (89 mM Tris base, 89 mM boric acid, and 2 mM EDTA), and 6 M 1 
urea.  Electrophoresis was performed in 1X TBE at 80 W for ~2 hours.  Products were 2 
visualized using a Typhoon 8600 Variable Mode Imager (Molecular Dynamics) as 3 
previously described (13).  Quantitation was performed using ImageQuant software 4 
(Molecular Dynamics) and fit by non-linear regression using KaleidaGraph 3.5 software 5 
(Synergy Software, Reading, PA).  6 
 7 
Thymidine Kinase Assay.  Purified recombinant HSV-1 TK and ganciclovir were a gift of 8 
Richard R. Drake (Eastern Virginia Medical School).  Nucleoside substrates were 9 
assayed as described previously(23).  The reaction mixture consisted of 0.01 – 1 mM 10 
nucleoside, 20 mM potassium phosphate (pH 7.6), 1mM DTT, 0.160 µM ATP, 0.106 µM 11 
α
32P-ATP (MP Biochemicals), 5 mM MgCl2, 25 mM NaF, 40 mM KCl, and 0.5 mg/ml 12 
bovine serum albumin.  The mixture was incubated for 5 minutes at 37° C for 5 minutes 13 
prior to addition of purified HSV-1 TK to a final concentration of 3.85 µg/ml.  The 14 
mixture was incubated at 37 °C for 5 minutes and then quenched by addition of EDTA 15 
(pH 8.0) to 80 mM.  One µl of the quenched reaction was spotted on PEI-cellulose F thin 16 
layer chromatography (TLC) plates (EMD Chemicals) and resolved with 300 mM 17 
potassium phosphate, pH 7.0.  The TLC plate was exposed to a phosphor screen 18 
(Molecular Dynamics) for 30 minutes and visualized using a Typhoon 8600 Variable 19 
Mode Imager (Molecular Dynamics).  Quantitation and curve fitting was performed using 20 

















Selection of HeLa S3 cell line expressing HSV-1 TK.  A mammalian expression plasmid 1 
containing the HSV-1 TK gene (pLTKEN) was provided by Richard R. Drake (Eastern 2 
Virginia Medical School)(32).  HeLa S3 cells were transfected with pLTKEN via 3 
lipofection with DMRIE-C reagent (Invitrogen) according to the manufacturer’s protocol.  4 
Stably transfected cells were selected in the presence of 0.4 mg/ml G418 sulfate 5 
(Invitrogen).  After 2 weeks of selection, 12 colonies were isolated, expanded, and 6 
screened for sensitivity to 25 µM ganciclovir.  Five clones demonstrating robust growth 7 
and sensitivity to ganciclovir were then screened for HSV-1 TK expression by lysing 8 
cells (4 × 107 cells/ml) in 1X Cell Culture Lysis Reagent (Promega).  Total protein 9 
concentration was determined by Bradford assay (Bio-rad Laboratories), and 15 µg 10 
protein from each sample was separated via SDS-PAGE using a 10% acrylamide gel 11 
followed by transfer to nitrocellulose.  HSV-1 TK was detected via Western blot using 12 
rabbit HSV-1 TK polyclonal antiserum (provided by Margaret E. Black, Washington 13 
State University) and goat anti-rabbit IgG-HRP.  The blot was developed using 14 
Amersham ECL Western Blotting Detection Reagents and exposed to X-ray film.  The 15 
clone showing the highest expression of HSV-1 TK (hereafter referred to as HeLa-TK) 16 
was expanded and used exclusively for further experiments. 17 
 18 
Nucleotide extraction from HeLa and HeLa-TK  cells.  Nucleotide extraction was 19 
modified from a previously published procedure(45).  7.5 x 106 HeLa S3 or HeLa-TK 20 
cells were plated in a 100-mm dish 15-18 hours before treatment.  Cells were treated with 21 
2.5 µg/ml actinomycin D (Sigma) for 15 minutes at 37 °C, and then rP was added to the 22 
















incubation, the media was aspirated, plates were washed with 5 ml phosphate-buffered 1 
saline (PBS), and 1 ml prewarmed trypsin-EDTA solution (Invitrogen) was added to each 2 
plate.  Cells were incubated for 5 minutes at 37 °C to facilitate detachment, after which 3 
cells were collected, pelleted, and resuspended in 0.05 ml ice-cold 0.6 M trichloroacetic 4 
acid (Sigma).  Cell suspension was incubated on ice for 10 minutes and then centrifuged 5 
at 14,000 x g for 2 minutes at 4 °C.  The supernantant was collected and extracted with 6 
an equal volume of  ice-cold 0.5 M trioctylamine in 1,1,2-trichlorotrifluoroethane 7 
(Sigma).  Samples were then vortexed for 30 s and centrifuged for 30s at 14,000 x g and 8 
4 °C.  The upper (aqueous) layer was removed and analyzed on a Hewlett Packard 1100 9 
series instrument equipped with an Aquasil C18 analytical column (4.6 x 250 mm, 5 µm; 10 
Keystone Scientific Inc., [Thermo Electron Corp.]) running the following mobile phase 11 
(flow rate 1 ml/min): gradient 1%-15% CH3CN in 100 mM potassium phosphate buffer 12 
(KH2PO4, pH = 6.0) over 20 mins, followed by 15-80% CH3CN in 100 mM KH2PO4 13 
buffer over 10 mins. 14 
 15 
Cells and viruses for cell-free translation and replication.  HeLa R19 cell monolayers 16 
and suspension cultures of HeLa S3 cells were maintained in DMEM supplemented with 17 
10% fetal bovine calf serum. Poliovirus for vRNA preparation was amplified on HeLa 18 
R19 cells as described previously (31). The infectivity of virus stocks was determined by 19 
plaque assays on HeLa R19 monolayers, as described previously(31).  20 
 21 
Preparation of poliovirus vRNA.  Virus stocks were grown and purified by CsCl gradient 22 
















mixture of phenol and chloroform. The purified RNA was precipitated by the addition of 1 
2 volumes of ethanol.   2 
 3 
Preparation of HeLa cytoplasmic extracts.  HeLa S10 extracts were prepared as 4 
previously described(8, 33) except for the following modifications: (I) packed cells from 5 
2 liters of HeLa S10 were resuspended in 1.0 volumes (relative to packed cell volume) of 6 
hypotonic buffer; (II) the final extracts were not dialyzed.   7 
 8 
Translation-RNA replication reactions with HeLa cell-free extracts and plaque assays.  9 
Viral RNA was translated at 34 °C in the presence of unlabeled methionine, 200 µM each 10 
CTP, GTP, UTP, and 1 mM ATP in a total volume of 25 µl(8, 33).  After incubation for 11 
12-15 hr the samples were diluted with phosphate-buffered saline and were added to 12 
HeLa cell monolayers. Virus titers were determined by plaque assay, as described 13 
previously(31). 1mM rPTP was added to the reaction as indicated.   14 
 15 
Translation-RNA replication reactions with HeLa cell-free extracts and in vitro 16 
translation.  Translation reactions (25 l) containing 8.8 µCi of Trans[35S]Label (ICN 17 
Biochemicals) and vRNA were incubated for 12 hr at 34 oC (8). 1mM rPTP was added to 18 
the reaction as indicated.  The samples were analyzed by electrophoresis on sodium 19 
deodecyl sulfate-12% polyacrylamide gels, followed by autoradiography.   20 
 21 
Translation-RNA replication reactions with HeLa cell-free extracts and luciferase assay.  22 
















replication reactions. The P/L replicon was linearized with DraI prior to transcription by 1 
T7 RNA polymerase. The transcript RNA was purified by phenol/chloroform extraction 2 
and ethanol precipitation.  After the P/L replicon was translated for 12 hr at 34 °C in the 3 
presence of unlabeled methionine, 200 µM each CTP, GTP, UTP, and 1 mM ATP in a 4 
total volume of 25 µl(8, 33, 34), the total reaction was transferred to a tube. 100 µl of 5 
luciferase assay reagent (Promega) was mixed with 25 µl of lysate, and the firefly 6 
luciferase activity was measured in an Optocomp I luminometer (MGM Instruments, 7 


















Incorporation of ribavirin triphosphate by T7 RNA polymerase.  Lethal 3 
mutagenesis as the mechanism of action of ribavirin could be supported by synthesizing 4 
poliovirus (PV) genomic RNA containing a known number of ribavirin monophosphate 5 
(RMP) substitutions and evaluating the phenotype of virus populations produced from 6 
these RNAs.  We investigated the ability of T7 RNA polymerase (T7 RNAP) to utilize 7 
ribavirin triphosphate (RTP) as a substrate by using a primer-extension assayAs shown in 8 
Figure 2, RTP was a poor substrate of T7 RNAP as compared with the correct 9 
nucleotides when either C or T was used as the first templating base.  Thus, poor 10 
incorporation of RTP by T7 RNA polymerase precludes its incorporation into PV 11 
genomic RNA in vitro at a frequency sufficient to reduce genome infectivity. 12 
 13 
Incorporation of rP into PV genomic RNA in vitro.  The nucleotide analogue 14 
rPTP has been established as an ambiguous substrate for T7 RNAP(35).  To determine 15 
the effect of rP incorporation into PV genomic RNA, rPTP was added along with all four 16 
naturally-occurring nucleotides during in vitro transcription of the PV genome by T7 17 
RNAP.  No significant reduction in the RNA yield by T7 transcription was observed 18 
when rPTP was added at up to 20% of the total nucleotide concentration, indicating that 19 
rPTP does not cause inhibition of RNA synthesis or premature termination when utilized 20 
as a substrate for T7 RNAP under these conditions (Figure 3C). 21 
To demonstrate incorporation of rPMP into transcribed RNA, the RNA was 22 
















residual nucleotides.  The RNA was then digested to its nucleoside constituents using 1 
nuclease P1 and shrimp alkaline phosphatase.  Nucleoside products were separated via 2 
reversed phase HPLC and detected by UV absorbance.  A peak corresponding to rP could 3 
be seen for RNA transcribed in the presence of PTP (Figure 3A).  The identity of each 4 
peak was verified by doping the RNA digest with standards of rP and all four naturally 5 
occurring nucleosides (data not shown). 6 
Quantitation of the rP peak in relation to the four naturally occuring nucleoside 7 
peaks provided a measure of the incorporation of rPMP into RNA by T7 RNAP when 8 
various concentrations of rPTP were added to the in vitro transcription reaction.  rP 9 
content of RNA increased linearly with increasing concentration of rPTP available during 10 
transcription (Figure 3B).  When rPTP was added equimolar to each of the 4 natural 11 
nucleotides (7 mM), 15% of the digested RNA product consisted of rP. 12 
 13 
Specific infectivity of PV genomic RNA containing rP.  The infectivity of PV 14 
genomic RNA containing rP was measured by infectious center assay as previously 15 
described(6).  PV genomic RNA was transcribed as described above and transfected into 16 
HeLa S3 cells by electroporation.  Serial dilutions of transfected cells were then added to 17 
subconfluent HeLa S3 monolayers and incubated under an agar overlay for 3 days.  18 
Replication-competent RNA genomes launch an authentic PV infection upon 19 
transfection, resulting in virus spread and a plaque in the cell monolayer.  This allows for 20 
quantitation of infectious RNA genomes. 21 
To determine the concentrations of RNA that would result in a linear response for 22 
















transfected into HeLa cells (Figure 4A).  The number of productively-infected cells (as 1 
measured by subsequent plaque formation) was found to be linear when up to 5 µg of 2 
RNA was transfected.  Three µg was used for all subsequent experiments. 3 
PV genomic RNA was transcribed by T7 RNAP in the presence of varying 4 
concentration of rPTP.  When this RNA was transfected into HeLa S3 cells, a rPTP-5 
dependent decrease in RNA infectivity was observed (Figure 4B).  Specific infectivity 6 
was defined as the number of plaques observed per µg of RNA per ml of transfected 7 
cells. Specific infectivity was normalized such that the number of plaques resulting from 8 
transfection with RNA containing no rPMP was set to 100.  Data described above for the 9 
amount of rP in RNA based on transcription conditions (Figure 3B) was extrapolated to 10 
estimate the number of rPMP incorporations per genome required to provide a given 11 
reduction in genome specific activity.  Approximately 20 molecules of rPTP incorporated 12 
per genome (~0.3% nucleotide composition) were sufficient for a 10-fold reduction in 13 
specific infectivity.  Thus, the presence of rP in viral genomes has a dramatic effect on 14 
the ability of those genomes to launch productive infections. 15 
 16 
Incorporation of rP into RNA by PV 3Dpol.  To confirm that rP acts as an 17 
ambiguous nucleoside during poliovirus replication, the ability of the PV RNA-18 
dependent RNA polymerase (3Dpol) to utilize rPTP as a substrate was determined using 19 
an in vitro primer-extension assay.  Symmetrical primer-template substrates (s/s) were 20 
utilized as previously described(2). Purified PV 3Dpol was mixed with RNA duplex 21 
primer/template for 90 s to allow for the formation of stable elongation complexes, at 22 
















post nucleotide addition and product was separated by denaturing PAGE (Figure 5).  1 
rPMP was efficiently incorporated into RNA by 3Dpol when the templating base was 2 
either adenosine or guanosine.  As indicated by the kpol/Kd,app, rPMP (from the rPTP 3 
substrate) was incorporated into RNA by PV 3Dpol approximately 100-fold more 4 
efficiently than incorporation of the known mutagen, ribavirin (Table 1).  Furthermore, 5 
incorporation was equally efficient opposite either adenosine or guanosine, confirming 6 
the promiscuous base pairing properties of rP (Figure 6A).  Incorporation was not 7 
detected when cytidine or uridine was utilized as the templating base (data not shown).   8 
Next, the ability of PV 3Dpol to further extend RNA having rPMP at the terminal 9 
3′ position was evaluated.  An extension reaction using s/s-A was performed as described 10 
above, but with ATP added to the reaction along with rPTP.  AMP should be 11 
incorporated in the second templated position immediately after incorporation of rPMP, 12 
resulting in quantitative extension of the 10-mer s/s-A substrate to a 12-mer product 13 
(Figure 6B).  AMP was found to be incorporated quantitatively as the +2 nucleotide, 14 
indicating that incorporation of rPMP does not result in “chain termination” by 15 
preventing further extension at the 3′ end of the RNA.  These experiments suggest that 16 
rPTP can be templated efficiently by either cytidine or uridine during poliovirus RNA 17 
replication and that incorporation of rPMP should not result in premature termination of 18 
the nascent RNA. 19 
 20 
Treatment of HeLa S3 cells with rP during PV infection.  In light of the 21 
observation that rPMP incorporation causes a reduction in specific infectivity of PV 22 
















HeLa S3 cells were pretreated with rP for 1 hour and infected with PV at a multiplicity of 1 
infection of 0.01 in order to maximize the cumulative effects of replication in the 2 
presence of a mutagen.  PV infection was allowed to proceed in the presence of rP until 3 
all cells demonstrated cytopathic effect (CPE), at which time virus was collected from the 4 
media and titered.  Treatment of cells with up to 2 mM rP failed to reduce the time 5 
required to reach CPE and did not cause a reduction in virus titer (data not shown).  6 
Furthermore, analysis of cellular nucleotide pools (as described below) failed to detect 7 
any phosphorylated rP metabolites in extracts of HeLa cells treated with 2 mM rP for 3 8 
hours (data not shown). 9 
 10 
rP is a substrate for HSV-1 thymidine kinase.  The failure of rP to exhibit 11 
antiviral activity could potentially be due to inefficient phosphorylation of the nucleoside 12 
by cellular nucleoside and nucleotide kinases, which would prevent accumulation of the 13 
nucleoside triphosphate necessary for incorporation into RNA.  The rate-limiting step for 14 
intracellular accumulation of a nucleoside triphosphate in cells is often the intital 15 
phosphorylation that results in production of the nucleoside monophosphate(55).  16 
Thymidine kinase (TK) from herpes simplex virus type 1 (HSV-1) is a nucleoside kinase 17 
with broad substrate specificity(44).  We examined the ability of HSV-1 TK to 18 
phosphorylate rP in vitro using purified HSV-1 TK.  For comparison, the natural 19 
substrate thymidine (T) and the anti-herpesvirus nucleoside analogue ganciclovir (GCV) 20 
were evaluated in parallel.  Steady-state kinetics produced the kinetic constants in Table 21 
2.  The kcat /Km  for rP was reduced 10-fold relative to that for T and 3-fold relative to that 22 
















phosphorylate rP in vitro with efficiency comparable to known in vivo nucleoside 1 
substrates. 2 
We reasoned that expression of HSV-1 TK in HeLa cells may be sufficient for 3 
activation of rP, resulting in antiviral activity due to lethal mutagenesis.  To this end, we 4 
introduced an HSV-1 TK expression plasmid conferring neomycin resistance(32) into 5 
HeLa cells and selected stably-transfected cells by addition of 400 µg/ml G418 sulfate to 6 
the culture media.  Colonies were screened for sensitivity to GCV, and then a Western 7 
blot was performed to assess the degree of expression of HSV-1 TK (data not shown).  8 
The colony with the most favorable expression, hereafter referred to as HeLa-TK, was 9 
expanded and used for subsequent experiments. 10 
 11 
Determination of intracellular phosphorylation states of rP in HeLa-TK cells.  12 
To investigate the intracellular metabolism of rP, HeLa-TK cells were treated with 2 mM 13 
rP for 3 hours, followed by nucleotide extraction and HPLC analysis of nucleotide pools 14 
as previously described(45).  Cells were treated with actinomycin D for 15 minutes prior 15 
to addition of rP to the media in order to prevent incorporation of phosphorylated rP 16 
metabolites into cellular RNA.  Phosphorylated forms of rP were not detected by this 17 
method (Figure 7).  However, the unmodified nucleoside was readily detected, indicating 18 
that the absence of phosphorylated metabolites was not due solely to exclusion of the 19 
nucleoside from the cytoplasmic compartment.  Furthermore, treatment with rP did not 20 

















P exhibits mild antiviral activity and mutagenesis of PV.  Treatment of HeLa 1 
cells with rP did not result in detectable levels of rPTP in cells and did not exhibit any 2 
observable antiviral effect or increased mutagenesis of PV genomes.  This may be due to 3 
the inability of rP to be phosphorylated through the cellular de novo nucleotide 4 
metabolism pathways.  However, administration of the nucleobase (P) might allow 5 
metabolism via the cellular nucleotide salvage enzymes, resulting in accumulation of the 6 
active triphosphate to sufficient intracellular levels.  To explore this possibility, we 7 
treated HeLa S3 cells with P at concentrations of up to 2 mM.  No overt cellular toxicity 8 
was observed by visual inspection through 3 days of continuous exposure to the 9 
nucleobase at these concentrations (data not shown). 10 
 P was tested for antiviral activity against PV under one step growth conditions.  11 
HeLa S3 cells were pretreated with P for one hour prior to infection with PV (MOI = 5).  12 
Fresh P in media was then added prior to incubation for 6 hours at 37 °C, followed by 13 
collection of cell-associated virus and determination of virus titer.  A mild decrease in 14 
titer was observed, approximately 2-fold at treatment of 0.5 mM or higher (Figure 8A). 15 
 To probe the mechanism responsible for this antiviral activity, mutation frequency 16 
of the resulting virus populations was estimated using a previously established assay for 17 
guanidine resistance(7).  Poliovirus replication is completely inhibited in the presence of 18 
3 mM guanidine hydrochloride, but a single transition mutation is sufficient to restore 19 
viability.  Hence, measurement of the frequency of guanidine-resistant PV variants can be 20 
used as an estimate of mutation frequency.  When PV, grown in the presence of varying 21 
















resistant variants was detected (Figure 8B).  However, this increase was not statistically 1 
significant when analyzed by ANOVA (P value >0.05)(37).  2 
 3 
Antiviral Activity of rPTP in PV cell-free replication system.  To examine the 4 
effects of rPTP on poliovirus infection, we utilized a well-established cell-free replication 5 
system utilizing HeLa cell extracts(33).  When programmed with PV genomic RNA, 6 
translation, replication, and production of infectious virus particles can be observed in 7 
these extracts.  Addition of 1 mM rPTP to the cell-free translation reaction resulted in no 8 
reduction in translation of replicon RNA as monitored by luciferase production, whereas 9 
addition of the translation inhibitor puromycin caused a complete block of luciferase 10 
production (Figure 9A).  Furthermore, no detectable effect on the processing of the PV 11 
polyprotein was observed in the presence of rPTP (Figure 9B).  However, infectious virus 12 
production in the presence of rPTP was reduced approximately 80-fold (Figure 9C).  13 
Because the presence of rPTP itself does not inhibit cell-free translation of the input 14 
RNA, the decreased infectivity of virus synthesized in cell extracts containing rPTP 15 
reflects a post-translational effect. 16 
 17 
rPTP substitution causes a replication defect in poliovirus subgenomic 18 
replicon.  To determine whether incorporated rPMP can affect virus replication, a 19 
poliovirus subgenomic replicon, wherein the capsid-coding region is replaced by a 20 
luciferase reporter(21), was transcribed in the presence of rPTP as previously 21 
described(18).  Reporter activity was monitored following transfection into HeLa S3 22 
















transfected, translation of input RNA was reduced approximately 50% as determined by 1 
incubation in the presence of 3 mM guanidine hydrochloride, a poliovirus replication 2 
inhibitor (Figure 10A, open symbols).  Translation was further diminished as additional 3 
rPMP substitutions were made (Figure 10B).  While this may reflect translational effects 4 
due to erroneous codon recognition of rPMP-containing RNA, it also likely reflects at 5 
least some loss of functionality due to mutation of the luciferase coding region induced 6 
by rPMP incorporation. 7 
rPMP-substituted RNA was transfected into HeLa cells and monitored for 8 
reporter activity over 8 hours (Figure 10A).  Genomes containing an average of 16.5 9 
substitutions per genomes exhibited diminished replication kinetics and approximately 10 
15-fold reduction in reporter activity at 8 hours.  Genomes containing an average of 1155 11 
substitutions per genomes exhibited no reporter activity in the presence or absence of 3 12 
mM guanidine hydrochloride. 13 
 14 
A high-fidelity PV variant shows increased sensitivity to rPTP incorporation.  15 
The preceding experiments suggest that incorporation of rPMP is deleterious to the PV 16 
genome through increased mutagenesis of the virus genomic sequence.  A high-fidelity 17 
PV (G64S) variant was previously identified as resistant to ribavirin treatment due to a 2-18 
fold increase in fidelity of the virus-encoded RNA-dependent RNA polymerase(4, 43).  If 19 
decreased infectivity of rPTP-containing genomes is due to increased mutagenesis, a 20 
high-fidelity variant should be less likely to “correct” those mutations during subsequent 21 
















Therefore, the high-fidelity G64S variant should be more sensitive to mutations 1 
introduced into the genome by T7 RNAP-mediated transcription. 2 
 We tested this hypothesis by transcribing both wild type (WT) and high fidelity 3 
(G64S) PV genomes in the presence of varying concentrations of rPTP.  These RNA 4 
genomes were transfected into HeLa cells via electroporation, and the transfected cells 5 
were added to growth media and incubated for 6 hours at 37 °C to allow for virus 6 
amplification over one replicative cycle.  Resultant virus populations were titered on 7 
HeLa monolayers.  The G64S variant showed increased sensitivity to rPTP genomic 8 
substitution (Figure 11).  At approximately 33 substitutions per genome, G64S virus titer 9 



















 Lethal mutagenesis as an antiviral strategy remains controversial, primarily due to 3 
the fact that mutagenesis alone has not been directly demonstrated to be sufficient for 4 
antiviral activity in vitro or in vivo.  Known nucleoside analogues, including ribavirin, 5 
generally have multiple pathways through which they can exert antiviral activity, 6 
including polymerase inhibition and perturbation of cellular nucleotide pools through 7 
interaction with the enzymes of nucleotide metabolism.  In addition, ribavirin and other 8 
purine analogues must compete with relatively large intracellular purine pools to act as 9 
effective mutagens.  Here we have demonstrated that mutagenesis of viral genomic RNA 10 
itself is sufficient for substantial reductions in virus infectivity.  While the nucleoside 11 
analogue evaluated herein did not exhibit antiviral activity in cell culture, we have 12 
directly demonstrated the application of lethal mutagenesis as an antiviral strategy, as 13 
well as the potential of nucleobase analogues with tautomeric constants near unity to act 14 
as lethal mutagens when used as substrates for RdRPs.  Further research in the area of 15 
tautomeric nucleobases should lead to analogues that are effective in vivo. 16 
Previous work has shown that rP and dP can be incorporated promiscuously by a 17 
number of RNA and DNA polymerases, respectively.  We demonstrate that rP is also 18 
recognized as an ambiguous pyrimdine analogue by a virus-encoded RNA-dependent 19 
RNA polymerase (PV 3Dpol).  Crotty and colleagues observed a 3.2-fold reduction in 20 
RNA specific infectivity when ribavirin-treated poliovirus genomic RNA was found to 21 
have 1.9 mutations per genome through sequencing of capsid-coding regions(6).  Here, 22 
















reduction in RNA specific infectivity.  This apparent discrepancy may be reconciled by 1 
noting that every incorporation event will not result in a mutation.  Furthermore, the 2 
tautomerization of P (KT approximately 11) favors the imino form (mimicking 3 
uridine)(20).  Accordingly, T7 RNA polymerase demonstrates a marked preference for 4 
recognition of rPTP as a uridine analogue(35).  Mutational assays in E. coli(40) and an in 5 
vitro retroviral replication model(36) both showed a bias towards C  U (or T) 6 
mutations over U (or T)  C by nearly a factor of 2, consistent with the imino form of P 7 
as the most thermodynamically favorable conformation. 8 
The loss of RNA infectivity when rPMP is incorporated into RNA may be due to 9 
a number of factors.  P is an ambiguously hydrogen bonding base, and its incorporation 10 
into genomic RNA should result in transition mutations. Thus, increased mutation of the 11 
coding sequence caused by genomic incorporation of rPMP may elicit loss of protein 12 
function, including the generation of dominant negative mutations.  Secondly, the 13 
unconventional structure of rP may preclude its recognition as part of a codon during 14 
RNA translation.  The presence of unnatural bases may also affect the stability of the 15 
RNA genome, resulting in more rapid degradation of the RNA in the cellular milieu.  16 
This can impact the infectivity of the genome if the effective lifetime of the molecule is 17 
too short to allow a productive infection to be established.  Finally, the presence of P may 18 
affect the ability of the RNA to form secondary and tertiary structures required for 19 
translation and virus replication.  Thus, mutation may affect not only the primary 20 
(protein-coding) sequence of the virus, but also the higher-order structures that are known 21 
















Inefficient phosphorylation of rP by cellular nucleotide and nucleoside kinases 1 
likely explains the lack of antiviral activity of this nucleoside in cell culture.  2 
Experiments performed with standards of the nucleoside indicated a lower limit of 3 
detection of approximately 1 nmole under the HPLC conditions employed (data not 4 
shown).  Based on the extraction conditions, this would allow detection of intracellular P 5 
metabolites present at approximately 20 µM or higher.  Our failure to detect any 6 
metabolites other than the ribonucleoside indicate that, even if rP can be recognized as a 7 
substrate for intracellular kinases, phosphorylated forms do not accumulate to high levels.  8 
Additionally, the ability to detect the nucleoside (rP) at substantial levels indicates that 9 
the lack of activity is likely not due to degradation or metabolism of the nucleoside, or 10 
failure of the nucleoside to accumulate intracellularly.  While our studies with the 11 
nucleobase (P) did exhibit demonstrate antiviral activity and mutagenesis (albeit 12 
statistically insignificant), this does not necessarily mean that rPTP accumulates 13 
intracellularly after treatment with the nucleobase. The nucleobase itself could have other 14 
activities which caused the observed mutagenic effect, such as perturbation of cellular 15 
nucleotide pools through interaction with the nucleotide biosynthetic enzymes of the cell. 16 
The failure to detect intracellular phosphorylated metabolites of rP highlights an 17 
important complication of nucleoside-based antiviral therapy, as relatively high levels of 18 
metabolically downstream nucleotides may need to be achieved for sufficient antiviral 19 
activity.  Mutagenic nucleoside analogues are prodrugs in that they must be activated by 20 
cellular enzymes (nucleoside and nucleotide kinases) in order for the active 21 
(triphosphorylated) form to accumulate.  The specificity of cellular nucleoside, 22 
















activity of nucleoside-based therapeutics.  A pronucleotide approach could potentially be 1 
utilized in delivering rPMP (or even rPTP) to cells, protecting the charged phosphates to 2 
allow cellular entry and liberation of the phosphorylated form in the cytoplasm by 3 
cellular metabolic enzymes (reviewed in(57)).  However, it is still unknown if available 4 
rPMP in the cytoplasm of mammalian cells will lead to accumulation of the 5 
triphosphorylated form (rPTP) and observable antiviral activity.  However, given the high 6 
capacity for mutagenesis exhibited by P, a prodrug of rP containing masked 5′ 7 
phosphates has the potential for significant antiviral activity. 8 
Lethal mutagenesis was proposed as an antiviral strategy almost 15 years ago.  9 
Despite this, previous attempts to design novel mutagenic nucleotide analogues that are 10 
capable of inducing mutation in RNA viruses have had only limited success(17-19, 39).  11 
In this study, we have demonstrated that rPTP is an efficient and ambiguous substrate of 12 
a viral RNA-dependent RNA polymerase.  rPTP was incorporated 100-fold more 13 
efficiently than the known mutagenic nucleoside ribavirin in vitro.  P therefore represents 14 
an important lead compound for the development of clinically useful antiviral therapies 15 
based on lethal mutagenesis of RNA virus genomes. 16 
Direct mutagenesis of viral RNA through T7-mediated transcription as described 17 
herein also holds potential for unraveling the sensitivity of RNA viruses to mutagenesis 18 
outside of the context of the virus-encoded polymerase.  A number of positive-sense 19 
RNA viruses have genomes that can be manipulated in vitro to examine the effects of 20 
mutational load on population fitness.  As such, this study introduces a potential 21 
methodology to screen for viruses that may exhibit enhanced sensitivity to lethal 22 
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FIGURE LEGENDS 1 
 2 
Figure 1. P basepairs with adenine and guanine.  P exists as two tautomers: imino-P 3 
and amino-P.  The former hydrogen bonds with adenine; the latter hydrogen bonds with 4 
guanine.  The imino-P to amino-P ratio is approximately 11:1(20). 5 
 6 
Figure 2.  RTP is not an efficient substrate for T7 RNAP.  (A) Substrates used for T7 7 
RNAP extension assay are illustrated with DNA template (top strand) and RNA primer 8 
(bottom strand).  Templating nucleotide is indicated in bold.  (B) Primer extension by T7 9 
RNAP is shown after 30 and 180 seconds when either RTP or the correct nucleotide was 10 
provided as substrate.  RMP was incorporated inefficiently when compared to the correct 11 
(natural) substrate.  Asterisk indicates 11-mer extended RNA substrate. 12 
 13 
Figure 3.  rPMP is incorporated into genomic RNA during transcription with T7 14 
RNAP.  (A) HPLC separation of RNA transcribed in the presence of rPTP.   RNA was 15 
digested to component nucleosides as described in the text.  rP was observed along with 16 
the four natural nucleosides.  (B) rPMP composition of RNA (as determined by HPLC of 17 
digested RNA) is plotted against concentration of rPTP present in the in vitro 18 
transcription reaction.  PV genome is 7.5 kb in length.  (C) RNA transcribed in the 19 
presence of increasing concentrations of rPTP was run on 1% agarose gel and stained 20 
with ethidium bromide.  Differences in RNA quality or length were not observed when 21 
rPTP was added to the transcription reaction at up to 20% of the total nucleotide pool.  L, 22 

















Figure 4.  rPMP incorporation into PV genomic RNA results in a dose-dependent 1 
decrease in specific infectivity.  (A) HeLa S3 cells were transfected with varying 2 
concentrations of in vitro transcribed RNA and serially diluted on HeLa S3 monolayers.  3 
Resulting plaques increased linearly up to ~5 µg.  (B) PV genomic RNA was transcribed 4 
in vitro in the presence of varying concentrations of rPTP and infectivity was determined 5 
by infectious center assay.  The number of rPMP incorporations per genome is plotted on 6 
the x-axis, as determined by extrapolating the data in Figure 3B for transcription in the 7 
presence of varying amounts of rPTP.  Specific infectivity was normalized such that for 8 
each experiment the number of plaques resulting from RNA transcribed in the absence of 9 
rPTP was set to 100.  The mean and standard deviation of at least 3 independent samples 10 
are shown for each data point.   11 
 12 
Figure 5.  PV polymerase incorporates rPMP opposite both adenine and guanine in 13 
RNA.  Either s/s-A [A] or s/s-G [B] was employed.  Utilization of rPTP was compared 14 
directly to utilization of the correct nucleotide: UTP [A]; or CTP [B].  Polymerase-s/s 15 
complexes were assembled and nucleotide added to a final concentration of 500 µM.  16 
Product formed after 15, 30, 45, 60, 120, 300, and 600 s was separated from substrate by 17 
denaturing PAGE and visualized by phosphorimaging.  Extended RNA product is 18 
indicated by the asterisks. 19 
 20 
Figure 6.  PV 3Dpol utilized rPTP more efficiently than ribavirin triphosphate.  (A) 21 
Poliovirus polymerase 3Dpol was incubated with s/s for 120 sec prior to initiating reaction 22 
















dashed lines represent fits of the data to a single exponential with kobs of 0.30 ± 0.02 s-1 
1and 0.44 ± 0.05 s-1 for rPMP incorporation opposite A (●) and G (■), and kobs of 0.008 ± 2 
0.001 s-1 and 0.009 ± 0.004 s-1 for rRMP incorporation across U (○) and C (□), 3 
respectively.  (B) Chain termination experiment was performed with s/s-A as described in 4 
Figure 6A.  Incorporation was monitored in the presence of rPTP alone (left panel) or in 5 
the presence of rPTP and ATP, the next correct nucleotide (right panel).  Quantitative 6 
incorporation of AMP was observed (n+2 product is indicated by the asterisk). 7 
 8 
Figure 7: rPTP is not detected in HeLa-TK cells treated with rP. (A) Separation of 9 
extracts from untreated HeLa-TK cells (100 µl injection). (B) Separation of extracts from 10 
HeLa-TK cells that were treated with 2 mM rP for 3 hours (100 µl injection). rP (tR =11.8 11 
min) is clearly observed in treated extracts. No new peaks with rPTP retention (tR =2.2 12 
min) or characteristic UV trace are observed. The absorbance wavelength for all traces is 13 
295 nm. 14 
 15 
Figure 8.  P exhibits mild antiviral and mutagenic properties.  (A) HeLa cells were 16 
pretreated for one hour with P and the infected with PV (MOI = 5) followed by 6 hours of 17 
incubation at 37 ° C.  Cell associated virus was recovered by freeze-thaw and titered.  18 
Experiments were performed in triplicate. (B) Guanidine resistance assay was performed 19 
in triplicate as described in the text. 20 
 21 
Figure 9.  Cell-free translation of PV genomic RNA is unaffected by the presence of 22 
















luciferase in place of the capsid-coding sequence. Translation was measured after 12 1 
hours via luciferase activity assay. (B) Cell-free reactions were programmed with PV 2 
viral RNA (vRNA).  After 12 hours of translation, products were separated via SDS-3 
PAGE. (C) Extracts were programmed with PV vRNA and viable virus produced was 4 
quantitated by plaque assay. 5 
 6 
Figure 10.  PV replicon containing rPMP shows a reduction in active luciferase 7 
reporter activity.  PV replicon contains luciferase reporter in place of the capsid-coding 8 
sequence.  Replicons were transcribed under conditions previously shown to result in 0, 9 
16.5, 33, or 82.5 rPMP substitutions per RNA molecule.  (A) Replicon-transfected cells 10 
were incubated in the presence or absence of 3 mM guanidine hydrochloride for 8 hours.  11 
(B)  Replicon-transfected cells were incubated for up to 3 hours in the presence of 3 mM 12 
guanidine hydrochloride.  Activity of the luciferase reporter was reduced by a maximum 13 
of 10-fold. 14 
 15 
Figure 11.  rPMP substitution in genomic RNA is more deleterious to a high-fidelity 16 
PV variant (G64S).  Cells were transfected by T7 RNAP-transcribed RNA containing a 17 
known number of rPMP substitutions, followed by incubation at 37 °C for 6 hours.  Cell-18 
associated virus was collected by freeze-thaw and titered.  Titers were normalized such 19 
that the titer of virus produced by RNA with no rPMP substitutions was set to 100.  The 20 
titer resulting from transfection of WT genomes containing no PTP was 2.3 ×106 PFU/ml; 21 

















Table 1. Kinetic and Thermodynamic Constants for PV 3Dpol-Catalyzed Nucleotide 
Incorporation 
Substrates  
Primer/templatea Nucleotide Kd,app (µM) kpol (s-1) kpol /Kd,app 
s/s -A     
 GCUAGGGCCC UTPb 98 ± 2 266 ± 2 2.7 
CCCGGGAUCG rPTP 134 ± 48 0.47 ± 0.05 0.0035 
     
s/s -C     
 GAUCGGGCCC GTPb 3.8 ± 0.7 57 ± 3 15 
CCCGGGCUAG RTPc 430 ± 79 0.019 ± 0.002 0.000044 
     
s/s-G     
 CAUGCCCGGG CTPb 19 ± 3 157 ± 8 8.2 
GGGCCCGUAC rPTP 132 ± 29 0.59 ± 0.05 0.0045 
     
s/s -U     
 CGAUGGGCCC ATPb 134 ± 18 86.7 ± 3.7 0.86 
CCCGGGUACG RTPc 496 ± 21 0.014 ± 0.001 0.000028 


















Table 2: Steady-state kinetic constants of HSV-1 thymidine kinase 
Nucleoside Km (µM) kcat (×10-3 s -1) kcat /Km (M-1s-1) 
T 1.7 ± 1.1 3.5 ± 0.3 2100 
GCV 7.8 ± 2.9 4.0 ± 0.3 510 




























































Graci, et al.            Figure 2
T-template C-template
NTP:      none     ATP             RTP         none      GTP           RTP


























Graci, et al.            Figure 3
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